Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856539 · ClinicalTrials.gov registry record · NA
ESP Block in MIS Lumbar Spine Surgery
A NA study of Patients With Spinal Stenosis Indicated for MIS TLIF, sponsored by Hospital for Special Surgery, New York.
- Recruiting
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05856539 is a NA study of Patients With Spinal Stenosis Indicated for MIS TLIF that is actively recruiting participants, run by Hospital for Special Surgery, New York. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05856539, a NA study of Patients With Spinal Stenosis Indicated for MIS TLIF, is actively recruiting participants, sponsored by Hospital for Special Surgery, New York.
- RECRUITING
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, randomized controlled trial of patients undergoing minimally invasive transforaminal lumbar interbody fusion. This study will randomize patients into one of two groups: erector spinae plane (ESP) block and no ESP block.
Conditions Studied
Interventions
- PROCEDURE Erector spinae plane (ESP) block
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2026-07-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05856539
The ClinicalTrials.gov registry entry for NCT05856539 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients With Spinal Stenosis Indicated for MIS TLIF appearing as the primary indexed condition, and to 1 intervention - of which Erector spinae plane (ESP) block is the first listed.
NCT05856539 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05856539 about?
NCT05856539 is a clinical study titled "ESP Block in MIS Lumbar Spine Surgery". This is a prospective, randomized controlled trial of patients undergoing minimally invasive transforaminal lumbar interbody fusion. This study will randomize patients into one of two groups: erector spinae plane (ESP) block and no ESP block.
What is the current status of trial NCT05856539?
This trial is currently recruiting. It is a NA study. The enrollment target is 48 participants. The study started on 2023-05-15. Estimated completion is 2026-07-15.
What conditions does trial NCT05856539 study?
This clinical trial studies the following conditions: Patients With Spinal Stenosis Indicated for MIS TLIF.
What interventions are being tested in trial NCT05856539?
The interventions under investigation include: Erector spinae plane (ESP) block (PROCEDURE).
Who is sponsoring clinical trial NCT05856539?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05856539 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.